PB2003: REAL-WORLD TREATMENT PATTERNS OF PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)

PB2003: REAL-WORLD TREATMENT PATTERNS OF PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)

Bibliographic Details
Main Authors:	Rami S. Komrokji, Leyla Hernandez- Donoso, Sejla Hodzic, Henry Owusu, Kevin Nolan, Claire Nourry, María Díez Campelo
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000974828.56432.7b

Similar Items

P541: REAL-WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)
by: Amer M. Zeidan, et al.
Published: (2023-08-01)

P778: LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) FROM THE MEDALIST TRIAL
by: P. Fenaux, et al.
Published: (2022-06-01)

Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
by: Andrew M. Brunner, et al.
Published: (2022-11-01)

P783: SYSTEMIC THERAPY UTILIZATION AND HEMATOLOGIC OUTCOMES IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FINDINGS FROM A REAL-WORLD MEDICAL RECORD REVIEW STUDY IN THE US, UK, AND EUROPE (EU)
by: M. Diez-Campelo, et al.
Published: (2022-06-01)

LUSPATERCEPT IN TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES: REAL WORLD DATA
by: Y. Gong, et al.
Published: (2024-01-01)

Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome
by: Panagiotis T. Diamantopoulos, et al.
Published: (2022-10-01)

PB1926: REAL-WORLD ERYTHROPOIESIS-STIMULATING AGENT (ESA) TREATMENT PATTERNS AND OUTCOMES AMONG US PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)
by: S. Mukherjee, et al.
Published: (2022-06-01)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
by: Oriol Calvete, et al.
Published: (2023-02-01)

Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine—A Retrospective Analysis
by: Kamil Wiśniewski, et al.
Published: (2024-03-01)

Trisomy X and myelodysplastic syndrome (MDS) with eosinophilia
by: Mohd Tohit, Eusni Rahayu, et al.
Published: (2012)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
by: Annika Kasprzak, et al.
Published: (2022-04-01)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
by: KS G&ouml;tze, et al.
Published: (2009-10-01)

Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country
by: Abdalla Awidi, et al.
Published: (2024-02-01)

S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
by: Matteo Giovanni Della Porta, et al.
Published: (2023-08-01)

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
by: Stahl, M, et al.
Published: (2023)

P788: FACTORS DRIVING TREATMENT DECISION IN PATIENTS WITH INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROME (MDS): A RETROSPECTIVE ANALYSIS FROM THE GRUPO ESPAÑOL DE SÍNDROMES MIELODISPLÁSICOS SPANISH MDS REGISTRY
by: M. Díez-Campelo, et al.
Published: (2022-06-01)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
by: Josephine Lucero, et al.
Published: (2023-06-01)

Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS)
by: Xiaoqing Xie, et al.
Published: (2021-12-01)

Cytogenetic study of Brazilian patients with myelodysplastic syndrome (MDS)
by: Tamara Borgonovo, et al.
Published: (2005-12-01)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
by: Efficace, F, et al.
Published: (2024)

P679: SPOTLIGHT ON THE REAL-WORLD TREATMENT OF CML PTS IN GERMANY: A RETROSPECTIVE SURVEY IN PRIVATE ONCOLOGY PRACTICES
by: Georg-Nikolaus Franke, et al.
Published: (2023-08-01)

S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)
by: Rami S. Komrokji, et al.
Published: (2023-08-01)

PB2026: ROLE OF MOLECULAR PROFILING IN MYELODYSPLASTIC SYNDROME IN REAL-WORLD - A NEW APPROACH IN MYELODYSPLASTIC SYNDROME’S RISK STRATIFICATION?
by: Duarte Pacheco Silva, et al.
Published: (2023-08-01)

P746: REAL-WORLD ANALYSIS OF A LARGE ELECTRONIC MEDICAL RECORD DATABASE OF PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): TREATMENT PROFILES, CLINICAL EFFECTIVENESS, AND KEY ADVERSE EVENTS
by: Rohan Shah, et al.
Published: (2023-08-01)

Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
by: Virginia O. Volpe, et al.
Published: (2021-01-01)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
by: Sabine Blum, et al.
Published: (2021-09-01)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
by: Fieke W. Hoff, et al.
Published: (2023-02-01)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
by: Abhishek A. Mangaonkar, et al.
Published: (2022-02-01)

Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
by: Rami S. Komrokji, et al.
Published: (2021-01-01)

Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series
by: Shamis Khan, et al.
Published: (2022-08-01)

PB2001: PROGNOSTIC FACTORS IN MYELODYSPLASTIC SYNDROMES- A SWEDISH RETROSPECTIVE REAL-WORLD STUDY
by: Frida Schain, et al.
Published: (2023-08-01)

P743: THE PIVOTAL ROLE OF GLUTAMINOLYSIS IN MYELODYSPLASTIC SYNDROME (MDS): A NOVEL STRATEGY FOR THE TARGETED THERAPY OF MDS
by: S. Okabe, et al.
Published: (2022-06-01)

THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (t-MDS) IN CHILDHOOD: THE EXPERIENCE OF THE HELLENIC STUDY GROUP FOR MDS/JMML/SAA, MEMBER OF THE EWOG-MDS/SAA WORKING GROUP
by: Loizos Petrikkos, et al.
Published: (2023-12-01)

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)
by: Axel Rüfer, et al.
Published: (2022-07-01)

P562: LEMZOPARLIMAB (LEMZO) WITH VENETOCLAX (VEN) AND/OR AZACITIDINE (AZA) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES (MDS): A PHASE 1B DOSE ESCALATION STUDY
by: J.-Z. Hou, et al.
Published: (2022-06-01)

Real-world trials to answer real-world questions.
by: Freemantle, N, et al.
Published: (2005)

Qualitative flow cytometric analysis of Malaysian myelodysplastic syndromes (MDS) patients.
by: Broojerdi, Mohadese Hashem, et al.
Published: (2012)

Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group
by: Mohamed Amine Bekadja, et al.
Published: (2023-04-01)

Current State and Challenges in Development of Targeted Therapies in Myelodysplastic Syndromes (MDS)
by: Michele Stanchina, et al.
Published: (2021-04-01)

P744: A REAL-WORLD STUDY OF MULTIPLE-CYCLE HYPOMETHYLATING AGENTS MONOTHERAPY IN MYELODYSPLASTIC SYNDROMES
by: Xiaozhen Liu, et al.
Published: (2023-08-01)